Very a short while ago, preliminary results from a 3rd trial evaluating ibrutinib vs . observation were introduced.one hundred and five Clients receiving ibrutinib experienced a longer occasion-absolutely free survival, but no overall survival advantage, although the results had been nonetheless imm